Key facts
- Corvia’s last known valuation is $105.2M (Jun 2022).
- It has raised $166.7M; the latest was Later Stage VC ($55.0M) in Jun 2025.
- Notable investors include General Catalyst, Arkin Capital, Third Rock Ventures, Accelmed, Edwards Lifesciences — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Corvia
- ·The full record, as it builds
Funding rounds
No funding rounds for Corvia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Corvia
Developer of a transcatheter device designed to reduce the symptoms or slow the progression of heart failure. The company's device treats heart failure by creating a small opening between the left and right atria to lower blood pressure in the left atrium and lungs, enabling patients to lead a healthy life by reducing the risk of heart failure.
- Sector
- Healthcare
- HQ
- Tewksbury, MA, United States
- Founded
- 2009
- Employees
- 40
- Website
- corviamedical.com/
- Ownership
- Privately Held (backing)
Corvia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Corvia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Corvia in its N-PORT filings yet. We sweep new filings monthly.